Difference in Therapeutic Effects between Roxadustat and Daprodustat, HIF-Ph Inhibitors, Depending on the Blood Type in Hemodialysis (HD) Patients

Abstract Human blood group antigens are glycoproteins and glycolipids expressed on the surface of red blood cells and a variety of human tissues. This study aimed to determine if there is an association between ABO blood type and the efficacy of HIF-PH inhibitors. Roxadustat and daprodustat are potent inhibitors of HIF-PH and capable of stimulating erythropoiesis in patients on patients with impaired renal function. These two compounds are reported to act mechanistically similar but display differences in their effects on cells, and the differences may affect their efficacy in the treatment of renal anemia in HD patients. In this study we compared the response rate by blood type between roxadustat and daprodustat, respectively. Sixty-eight HD patients treated with roxadustat (20-100mg, 3/week) and ninety-five treated with daprodustat (1-12mg, daily) were recruited in our observational study. We defined >1.5g/dL increase in hemoglobin as effective, and <1.5g/dL decrease as ineffective. As shown in the figure, type A had a significantly high response rate at 47% in HD patients treated with roxadustat. On the other hand, type O had a significantly high response rate at 55% in those who were treated with daprodustat. We found the association in the effectiveness of roxadustat on the treatment for anemia in HD patients in type A, while the effectiveness was higher in type O treated with daprodustat. The results suggest that the therapeutic effect of HIF-PH inhibitors may differ depending on the blood type. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.

Download Full-text

Associations of ABO blood type and galactose-deficient immunoglobulin A1 with adverse outcomes in patients with IgA nephropathy

Nephrology Dialysis Transplantation ◽

10.1093/ndt/gfz171 ◽

2019 ◽

Cited By ~ 1

Author(s):

Manliu Wang ◽

Jicheng Lv ◽

Pei Chen ◽

Guizhen Yu ◽

Sufang Shi ◽

...

Keyword(s):

Iga Nephropathy ◽

Cox Regression ◽

Type A ◽

Adverse Outcomes ◽

Blood Type ◽

Blood Group Antigens ◽

Type B ◽

Progression Of Kidney Disease ◽

Abo Blood Type

Abstract Background Both ABO blood group antigens and pathogenic immunoglobulin A1 (IgA1) in patients with IgA nephropathy (IgAN) are influenced by modifications of N-acetylgalactosamine and galactose. The purpose of this study was to assess whether ABO blood type is associated with galactose-deficient IgA1 (Gd-IgA1) in the progression of kidney disease in patients with IgAN. Methods We enrolled 1313 IgAN patients with a median of 44 months follow-up and measured the plasma Gd-IgA1 levels. Multivariate Cox regression models were used to estimate the association between all variables and adverse outcomes. Using the propensity score matching method, 718 IgAN patients with blood type either A or B were selected, and their data were used to assess the association of blood type and Gd-IgA1/serum complement 3 (sC3) with outcomes. Results We found that the risk of adverse outcomes was significantly higher in patients with blood type A than in those with type B (hazard ratio = 1.82, 95% confidence interval 1.23–2.71; P = 0.003) after multivariate adjustment. The Gd-IgA1 levels showed trends similar to the multivariate-adjusted event-free curves for the blood types. However, this higher risk of adverse outcomes in type A than in type B patients was no longer significant after the addition of Gd-IgA1/sC3 to the model. Conclusions IgAN patients with blood type A had a higher risk of adverse outcomes than those with type B, and this risk was associated with Gd-IgA1/sC3. Thus, the ABO blood type may provide a reference for the prognostic factors for individuals with IgAN.

Download Full-text

Reduced-Dosage of Three Drugs Combination of Cyclophosphamide, Bortezomib and Dexamethasone (reduced-CyBorD) Retains High Response Rate with Less Toxicities in Elderly Patients with Multiple Myeloma

Blood ◽

10.1182/blood.v120.21.1865.1865 ◽

2012 ◽

Vol 120 (21) ◽

pp. 1865-1865 ◽

Cited By ~ 1

Author(s):

Hideo Yagi ◽

Ryosuke Fujiwara ◽

Keigo Sano ◽

Fujita Mariko ◽

Takashi Iizuka ◽

...

Keyword(s):

Multiple Myeloma ◽

Adverse Events ◽

Elderly Patients ◽

Response Rate ◽

Conflicts Of Interest ◽

High Response Rate ◽

High Response ◽

High Dose ◽

Weekly Schedule ◽

High Dose Dexamethasone

Abstract Abstract 1865 Background: The three drugs combination of cyclophosphamide, bortezomib and dexamethasone (CyBorD) has been proven to be a powerful regimen for the treatment of the patients with multiple myeloma (MM). However, twice-weekly schedule of bortezomib and high dose dexamethasone has been shown to cause significant toxicities, including severe peripheral neuropathy (PN). Recently, once-weekly bortezomib induction therapy with CyBorD (modified-CyBorD) has shown less toxicity with high response rate equal to original regimen (Reeder, CB et al. Leukemia 2009). However, more than half of the patients developed bortezomib induced PN (BiPN) in modified-CyBorD. Thus it was still concerned adverse event for the transplant ineligible patients, especially frail elderly patients because it often caused interruption or withdrawal of the treatments, resulting in fewer efficacies. Under these circumstances, we introduced the reduced-dosage of CyBorD regimen (reduced-CyBorD) in the transplant ineligible patients with multiple myeloma for continuation of the treatment. Methods: The protocol consisted of bortezomib given intravenously at a dose of 1.3 mg/m2once a week on days 1, 8, 15, cyclophosphamide orally at a dose of 50 mg daily on days 1–21, and dexamethasone orally or intravenously at a dose of 20 mg daily on days 1,2,8,9,15,16 in 4-week cycles. Total of 20 patients, including 12 newly diagnosed and 8 refractory, were treated with reduced-CyBorD and evaluated its efficacy and safety. Results: The median age was 72 years (range from 62 to 81). 14 patients were more than 70 year-old (70%). A half of the patients were female. According ISS, 3 patients were classified in stage I, 6 were in II, and 11 were in III. The overall response was 86.6 % with 26.7 % CR/nCR (1 CR, 3 nCR, 5 VGPR and 4 PR). Hematological adverse events were neutropenia (35%; G1/2 n=7), lymphocytopenia (35%; G1/2 n=1, G3/4, n=1), thrombocytopenia (10%; G1/2 n=2). Non-hematological adverse events were pneumonia (20%; G2 n=2, G3 n=2), VZV infection (15%; G2 n=3), cerebral infarction (5%; G2 n=1). Importantly, only three patients (15%) developed grade 1 PN, and no patient reduced or discontinued bortezomib due to PN. Conclusions: Reduced-CyBorD with three times once-weekly bortezomib retained high efficacy seen in standard and modified CyBorD (4 times bortezomib administration). Furthermore, it was found that this regimen obviously revealed less toxicity, especially BiPN compared with those previous regimens (See Table). Our results suggested that reduced-CyBorD might be safe and effective approach to the transplant ineligible patients, especially elderly frail patients with MM. Disclosures: No relevant conflicts of interest to declare.

Download Full-text

High response rate to combined chemotherapy avoiding radiotherapy in children and adolescents with classical Hodgkin lymphoma. Preliminary results of GALOP LH 2017 Protocol

10.1055/s-0040-1701859 ◽

2020 ◽

Author(s):

EM Alfaro ◽

M Schelotto ◽

M Guitter ◽

C Sanchez ◽

L Peruzzo ◽

...

Keyword(s):

Children And Adolescents ◽

Hodgkin Lymphoma ◽

Response Rate ◽

High Response Rate ◽

High Response ◽

Combined Chemotherapy ◽

Classical Hodgkin Lymphoma ◽

Preliminary Results

Download Full-text

High response rate to recombinant influenza vaccine

Inpharma Weekly ◽

10.2165/00128413-199610400-00019 ◽

1996 ◽

Vol &NA; (1040) ◽

pp. 8

Author(s):

&NA;

Keyword(s):

Influenza Vaccine ◽

Response Rate ◽

High Response Rate ◽

High Response

Download Full-text

Multiple myeloma patients experience high response rate with new three-drug combination

Cancer Biology & Therapy ◽

10.4161/cbt.8.24.11003 ◽

2009 ◽

Vol 8 (24) ◽

pp. 2317-2320

Keyword(s):

Multiple Myeloma ◽

Drug Combination ◽

Response Rate ◽

High Response Rate ◽

High Response ◽

Patients Experience

Download Full-text

A Follow-up Investigation with High Response Rate

Scandinavian Journal of Social Medicine ◽

10.1177/140349488801600302 ◽

1988 ◽

Vol 16 (3) ◽

pp. 137-137

Author(s):

Henrik Toft Sørensen ◽

Bo Christensen ◽

Erling Kjærulff

Keyword(s):

Response Rate ◽

High Response Rate ◽

High Response

Download Full-text

ABO blood type and risk of porcine bioprosthetic aortic valve degeneration: SWEDEHEART observational cohort study

BMJ Open ◽

10.1136/bmjopen-2019-029109 ◽

2019 ◽

Vol 9 (5) ◽

pp. e029109 ◽

Cited By ~ 1

Author(s):

Michael Persson ◽

Gustaf Edgren ◽

Magnus Dalén ◽

Natalie Glaser ◽

Martin L Olsson ◽

...

Keyword(s):

Heart Failure ◽

Cohort Study ◽

Aortic Valve ◽

Aortic Valve Replacement ◽

Valve Replacement ◽

Type A ◽

Blood Type ◽

Type B ◽

Structural Valve Deterioration ◽

Abo Blood Type

ObjectiveBlood type A antigen on porcine aortic bioprostheses might initiate an immune reaction leading to an increased frequency of structural valve deterioration in patients with blood type B or O. The aim was to analyse the association between ABO blood type and porcine bioprosthetic aortic valve degeneration.DesignObservational nationwide cohort study.SettingSwedish population-based study.ParticipantsAdult patients (n=3417) who underwent surgical aortic valve replacement and received porcine bioprosthetic aortic valves between 1995 and 2012 from the Swedish Web system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies register. The study database was enriched with information from other national registers.ExposureThe patients were categorised into type A/AB and type B/O blood groups.Primary and secondary outcome measuresPrimary outcome measure was aortic valve reoperation, and secondary outcomes were heart failure and all-cause mortality. We report risk estimates that account for the competing risk of death.ResultsIn total, 3417 patients were identified: 1724 (50.5%) with blood type A/AB and 1693 (49.5%) with blood type B/O. Both groups had similar baseline characteristics. The cumulative incidence of aortic valve reoperation was 3.4% (95% CI 2.5% to 4.4%) and 3.6% (95% CI 2.6% to 4.6%) in the type B/O and the A/AB group, respectively, at 15 years of follow-up (absolute risk difference: −0.2% (95% CI −1.5% to 1.2%)). There was no significantly increased risk for aortic valve reoperation in patients with blood type B/O compared with type A/AB (HR 0.95, 95% CI 0.62 to 1.45). There was no significant difference in absolute or relative risk of heart failure or death between the groups.ConclusionsWe found no significant association between patient blood type and clinical manifestations of structural valve deterioration following porcine aortic valve replacement. Our findings suggest that it is safe to use porcine bioprosthetic valves without consideration of ABO blood type in the recipient.Trial registration numberNCT02276950

Download Full-text